How much will Herceptin really cost?

作者: Ann Barrett , Tom Roques , Matthew Small , Richard D Smith

DOI: 10.1136/BMJ.39008.624051.BE

关键词:

摘要: New guidance from the National Institute for Health and Clinical Excellence recommends Herceptin in early breast cancer, but it provides no additional funding or any suggestion of which services to cut. This leaves medical staff with difficult decisions make

参考文章(14)
Virginia Wiseman, Karen Gerard, Craig Mitton, Stephen Jan, Cam Donaldson, Economics of Health Care Financing: The Visible Hand ,(2004)
Rebecca Dent, Mark Clemons, Adjuvant trastuzumab for breast cancer BMJ. ,vol. 331, pp. 1035- 1036 ,(2005) , 10.1136/BMJ.331.7524.1035
John McKie, Jeff Richardson, The Rule of Rescue Social Science & Medicine. ,vol. 56, pp. 2407- 2419 ,(2003) , 10.1016/S0277-9536(02)00244-7
Helen Angela Dakin, Nancy J. Devlin, Isaac A.O. Odeyemi, "Yes", "No" or "Yes, but"? Multinomial modelling of NICE decision-making. Health Policy. ,vol. 77, pp. 352- 367 ,(2006) , 10.1016/J.HEALTHPOL.2005.08.008
Nancy Devlin, John Appleby, David Parkin, Patients' views of explicit rationing: what are the implications for health service decision-making? Journal of Health Services Research & Policy. ,vol. 8, pp. 183- 186 ,(2003) , 10.1258/135581903322029557
Wendy Rogers, Who should we treat? Rights, Rationing and Resources in the NHS Health Expectations. ,vol. 9, pp. 197- 199 ,(2006) , 10.1111/J.1369-7625.2006.00389.X
Michael D Rawlins, Anthony J Culyer, National Institute for Clinical Excellence and its value judgments BMJ. ,vol. 329, pp. 224- 227 ,(2004) , 10.1136/BMJ.329.7459.224